Provided by Tiger Trade Technology Pte. Ltd.

Aktis Oncology

23.79
-0.1500-0.63%
Volume:135.12K
Turnover:3.22M
Market Cap:1.32B
PE:-19.61
High:24.54
Open:24.36
Low:23.42
Close:23.94
52wk High:34.19
52wk Low:14.72
Shares:55.28M
Float Shares:17.65M
Volume Ratio:0.50
T/O Rate:0.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2134
EPS(LYR):-78.3394
ROE:-29.45%
ROA:-15.79%
PB:2.71
PE(LYR):-0.30

Loading ...

Aktis Oncology Initiated at Outperform by Oppenheimer

Dow Jones
·
Sep 09

Aktis Oncology Inc : Oppenheimer Initiates Coverage with Outperform Rating; Price Target $40

THOMSON REUTERS
·
Sep 09

Oppenheimer Initiates Coverage on Akoustis Technologies With Outperform Rating, $40 PT

MT Newswires Live
·
Sep 09

Aktis Oncology to Present at Upcoming September Investor Conferences

GlobeNewswire
·
Sep 09

Aktis Oncology initiated with an Outperform at Oppenheimer

TIPRANKS
·
Sep 09

Aktis Oncology Seen Advancing Targeted Radiation-Based Cancer Drugs, Wedbush Says

MT Newswires Live
·
Aug 19

Wedbush Initiates Aktis Oncology at Outperform With $35 Price Target

MT Newswires Live
·
Aug 19

Aktis Oncology initiated with an Outperform at Wedbush

TIPRANKS
·
Aug 19

Aktis Oncology Inc : Bmo Initiates Coverage with Outperform Rating; Price Target $37

THOMSON REUTERS
·
Aug 19

16 Beaten-Down AI Stocks That Are Beloved by BofA Analysts

Dow Jones
·
Aug 17

Cancer Diagnostics Firm Precipio's Q2 Revenue Rises, Adjusted Ebitda Turns Positive

Reuters
·
Aug 15

Moleculin Biotech Expects Cash Position to Fund Operations into Q1 2027

Reuters
·
Aug 14

Analysts Have Conflicting Sentiments on These NA Companies: Aktis Oncology, Inc. (AKTS), Bullish (BLSH) and SanDisk Corp (SNDK)

TIPRANKS
·
Aug 14

Analysts Are Bullish on Top NA Stocks: Aktis Oncology, Inc. (AKTS), Yesway Inc Class A (YSWY)

TIPRANKS
·
Aug 14

Corrected-Aktis Oncology Q2 Operating Income USD -28.899 Million (Corrects Source, Period)

THOMSON REUTERS
·
Aug 14

UK's Akari Therapeutics Q2 Net Loss Widens on Higher R&D for AKTX-101

Reuters
·
Aug 14

Aktis Oncology Q2 EPS $(0.44) Misses $(0.43) Estimate, Sales $3.384M Beat $2.000M Estimate

Benzinga Earnings
·
Aug 14

Genelux Posts Wider-than-Expected Q2 Loss on Higher R&D Expenses

Reuters
·
Aug 14

Aktis Oncology Q2 FY26 Net Loss Widens 33.15% to $24.1 Million

Reuters
·
Aug 14

Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026

THOMSON REUTERS
·
Aug 14